Response: 'letter to the editor: emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa'.

IF 2.7 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Opinion on Emerging Drugs Pub Date : 2022-12-01 DOI:10.1080/14728214.2022.2152212

Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E MacLaren

引用次数: 0

查看原文本刊更多论文

回复：致编辑的信：RPGR 相关 X 连锁色素性视网膜炎的新兴基因治疗产品"。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Emerging Drugs 医学-药学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.